MMG Introduces Enhanced Education Platform for Clinical Trials
MMG announced an exclusive strategic partnership with online healthcare communications company MedRespond to introduce Custom Conversations
MMG, a global health communications company specializing in clinical trial patient recruitment and retention, announced an exclusive strategic partnership with online healthcare communications company MedRespond to introduce Custom Conversations, its new technological advancement in clinical trial patient education.
Custom Conversations uses video, natural language query capabilities, and the Internet to allow people exploring clinical trial options to have a more customized online learning interaction. An advanced synthetic interview technology developed by Carnegie Mellon University, allows people to also can ask questions in their own words, and then receive pre-recorded video responses which have been pre-approved by the study’s institutional review board or ethics committee.
According to MMG, pilot programs have shown clear boosts in enrollment rates compared to trials for which patients received only traditional study educational materials.
The Custom Conversations platform can be also be leveraged throughout the study education continuum – from first learning about a study, to pre-qualification and screening, and for the duration of the study, which can help to fortify retention. Sponsors receive insight into the anonymous activity data to get a view into patients’ and caregivers’ communication needs and mindsets, which can be used to refine recruitment and retention strategies and messaging.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
